VanEck Biotech ETF (BBH)
| Assets | $475.49M |
| Expense Ratio | 0.35% |
| PE Ratio | 29.08 |
| Forward PE | 20.27 |
| Shares Out | 2.02M |
| Dividend | $0.96 (0.39%) |
| Ex-Dividend Date | Dec 22, 2025 |
| Payout Frequency | Annual |
| Payout Ratio | 10.60% |
| Volume | 14,222 |
| Open | 244.17 |
| Previous Close | 241.07 |
| Day's Range | 244.15 - 247.90 |
| 52-Week Low | 172.92 |
| 52-Week High | 247.90 |
| Beta | 0.68 |
| Holdings | 26 |
| Inception Date | Dec 20, 2011 |
About BBH
Fund Home PageThe VanEck Biotech ETF (BBH) is an exchange-traded fund that is based on the MVIS US Listed Biotech 25 index, a market-cap-weighted index of the 25 largest biotech firms globally. BBH was launched on Dec 20, 2011 and is issued by VanEck.
Top 10 Holdings
72.96% of assets| Name | Symbol | Weight |
|---|---|---|
| Amgen Inc. | AMGN | 15.97% |
| Gilead Sciences, Inc. | GILD | 13.52% |
| Vertex Pharmaceuticals Incorporated | VRTX | 7.88% |
| Moderna, Inc. | MRNA | 7.04% |
| Regeneron Pharmaceuticals, Inc. | REGN | 6.67% |
| Natera, Inc. | NTRA | 5.29% |
| IQVIA Holdings Inc. | IQV | 4.48% |
| Illumina, Inc. | ILMN | 4.14% |
| Revolution Medicines, Inc. | RVMD | 4.00% |
| argenx SE | ARGX | 3.97% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 22, 2025 | $0.9565 | Dec 26, 2025 |
| Dec 23, 2024 | $1.2517 | Dec 24, 2024 |
| Dec 18, 2023 | $0.7127 | Dec 22, 2023 |
| Dec 19, 2022 | $0.7488 | Dec 23, 2022 |
| Dec 20, 2021 | $0.3972 | Dec 27, 2021 |
| Dec 21, 2020 | $0.6079 | Dec 28, 2020 |
Performance
BBH had a total return of 42.77% in the past year, including dividends. Since the fund's inception, the average annual return has been 14.23%.
News
Retension Pharmaceuticals, TRex Bio file for US IPO as biotech momentum continues
Drug developers Retension Pharmaceuticals and TRex Bio filed their paperwork for U.S. initial public offerings on Friday, reinforcing the biotech pipeline for the fall IPO window.
BIO CEO says more consistency needed in FDA review process
U.S. biotechnology industry trade group BIO worked with the Food and Drug Administration on plans announced on Monday to speed clinical trials and expects the next initiative will aim to standardize...
Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz
Jared Holz, Mizuho healthcare strategist, joins 'Power Lunch' to discuss the change in sentiment in the healthcare sector, the differences in the biotech ETFs and much more.
ETF Investors Indicate Active Strategies and Product Innovation Will Fuel the Industry's Continued Growth: BBH 2024 Global ETF Investor Survey
BOSTON--(BUSINESS WIRE)--As the ETF industry reaches a milestone of $12.71 trillion in global assets, the Brown Brothers Harriman 2024 Global ETF Investor Survey finds that investors plan to further i...
Brown Brothers Harriman Private Banking Team Expands in Philadelphia
PHILADELPHIA--(BUSINESS WIRE)--The Private Banking arm of Brown Brothers Harriman & Co. (BBH) is pleased to announce the expansion and strengthening of its Corporate Advisory and Banking team in Phi...
Biotech ETFs at multi-week highs, extending winning streak
Biotechnology exchange-traded funds outperformed Tuesday as investors focused on next-generation solutions to the coronavirus and more. The ARK Genomic Revolution ETF was up 2.2% in the early afternoo...